Literature DB >> 10900222

The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.

M O'Brien1, G D Kruh, K D Tew.   

Abstract

Glutathione (GSH), glutathione S-transferases (GSTs), and the multidrug resistance-associated protein 1 (MRP1) have been independently studied for their contributions to drug resistance. Single cDNA transfection experiments have provided inconsistent and disparate conclusions with respect to the importance of GSH and GST in conferring a resistant phenotype. Because these three proteins can act as a concerted coordinated pathway, we reasoned that equivalent increases may be required for enhanced resistance to be expressed. We have assembled these proteins together, or in various combinations, to determine whether they show cooperativity in determining drug response. Increased expression through single cDNA transfection of GSTpi, gamma-glutamylcysteine synthetase (gamma-GCS) (regulatory plus catalytic subunits), or MRP1 enhanced resistance to a number of anticancer drugs. Cotransfection of GSTpi and GCS, gave higher resistance to doxorubicin, etoposide, and vincristine than with either alone. Resistance toward chlorambucil and ethacrynic acid was similar in cells overexpressing either component or overexpressing GST alone. Coexpression of GSTpi with MRP1 conferred significant resistance above that seen for MRP1 alone to chlorambucil, etoposide, ethacrynic acid, and vincristine. The combination of GCS and MRP1 did not afford additional resistance above MRP1 alone. When all three were transfected, significantly higher levels of resistance were found for doxorubicin and etoposide. These results support the concept that coordinate enhancement of focal thiol elements of detoxification pathways provides a more efficient protective phenotype than do single components alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900222

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

2.  Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.

Authors:  Charalambos Andreadis; Phyllis A Gimotty; Peter Wahl; Rachel Hammond; Jane Houldsworth; Stephen J Schuster; Timothy R Rebbeck
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

3.  Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Authors:  Patrick Thompson; Heather E Wheeler; Shannon M Delaney; Rachel Lorier; Ulrich Broeckel; Meenakshi Devidas; Gregory H Reaman; Kathleen Scorsone; Lillian Sung; M Eileen Dolan; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-14       Impact factor: 3.333

4.  Integrated stress response modulates cellular redox state via induction of cystathionine γ-lyase: cross-talk between integrated stress response and thiol metabolism.

Authors:  Jeffrey G Dickhout; Rachel E Carlisle; Danielle E Jerome; Zahraa Mohammed-Ali; Hua Jiang; Guangdong Yang; Sarathi Mani; Sanjay K Garg; Ruma Banerjee; Randal J Kaufman; Kenneth N Maclean; Rui Wang; Richard C Austin
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

5.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  The metabolic bioactivation of caffeic acid phenethyl ester (CAPE) mediated by tyrosinase selectively inhibits glutathione S-transferase.

Authors:  Shashi K Kudugunti; Helen Thorsheim; Mohammad S Yousef; Lan Guan; Majid Y Moridani
Journal:  Chem Biol Interact       Date:  2011-03-31       Impact factor: 5.192

Review 7.  Glutathione-s-transferases as determinants of cell survival and death.

Authors:  Kenneth D Tew; Danyelle M Townsend
Journal:  Antioxid Redox Signal       Date:  2012-06-13       Impact factor: 8.401

8.  Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

Authors:  R Zarate; J Rodríguez; E Bandres; A Patiño-Garcia; M Ponz-Sarvise; A Viudez; N Ramirez; N Bitarte; A Chopitea; J Gacía-Foncillas
Journal:  Br J Cancer       Date:  2010-03-09       Impact factor: 7.640

9.  Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Thomas C Wilde; Michael L Citro; Michael M Goodblatt; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

10.  Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.

Authors:  Marco Agostini; Lara Maria Pasetto; Salvatore Pucciarelli; Salvatore Terrazzino; Alessandro Ambrosi; Chiara Bedin; Francesca Galdi; Maria Luisa Friso; Claudia Mescoli; Emanuele Urso; Alberta Leon; Mario Lise; Donato Nitti
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.